becton dickinson annual report

All rights reserved. As a purpose-driven organization with global health impact and a strong set of values, behaviors and commitments - what we call The BD Way - an emphasis on environmental, social and governance (ESG) issues is central to our identity as a good, corporate citizen. The company stock has a Forward Dividend ratio of 3.48, while the dividend yield is 1.58%. The Annual Meeting of Shareholders of Becton, Dickinson and Company, a New Jersey corporation ("BD"), will be held on Tuesday, January 26, 2021, at 1:00 p.m. Eastern Time (the "2021 Annual Meeting"). Report Locked. Becton Dickinson is a medical technology company, which manufactures and sells medical devices, reagents, and instruments. respective owners. I see this giving rise to three irreversible forces that are going to be shaping healthcare in new ways: Smart Connected Care - AI, informatics and robotics will transform healthcare processes, tools and treatments. FRANKLIN LAKES - BD , a leading global medical technology company, today released its inaugural cybersecurity annual report, becoming the first medical technology company to update stakeholders. Support. And with the help of a dedicated and passionate global team more than 75,000 associates strong, we are committed to executing our plans and broadening our legacy of impactful, transformative innovation as we reinvent the future of healthcare for the benefit of patients, customers and shareholders worldwide. Becton Dickinson and : 2021 Annual Report 12/13/2021 GMT Made for what's next in health Annual Report 2021 BD associates have a passion and commitment to help improve outcomes by advancing clinical therapy for patients, optimizing clinical processes for healthcare providers and enhancing safety for patients and healthcare workers. Morgan Stanley Raises Becton, Dickinson and Company's Price Target to $275 From $272, R.. Goldman Sachs Raises Price Target on Becton Dickinson to $319 From $278, Maintains Buy .. Stifel Nicolaus Adjusts Becton, Dickinson and Company's Price Target to $280 From $290,.. Chairman, President & Chief Executive Officer, Chief Financial Officer & Executive Vice President, Chief Medical Officer & Executive Vice President, Senior Vice President-Research & Development, Chief Scientific Officer & Senior Vice President. Becton Dickinson Co (BDX) 10-K Annual Report Wed Nov 26 2014; SEC Filings. becton-dickinson-annual-report 1/3 Downloaded from appcontent.compassion.com on October 18, 2022 by Mia u Boyle Becton Dickinson Annual Report File Name: becton-dickinson-annual-report.pdf Size: 3365 KB Type: PDF, ePub, eBook Category: Book Uploaded: 2022-10-08 Rating: 4.6/5 from 566 votes. The ubiquity of BD devices in the healthcare setting creates a very stable business that weathers storms and uncertainty. Annual Reports. Returning capital to shareholders will remain a key component of our capital allocation framework. EARNINGS; TRENDING; STOCKTWITS; . BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD has 76,032 employees, and the revenue per employee ratio is $225,128. Questions for the Investor Relations department can be addressed to: BD All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. One such example is in vascular access, where we are seeking to redefine the standard of care with a focus on the patient experience - a vision we call the "One Stick Hospital Stay" - which would leverage our fiscal 2021 acquisition of Velano Vascular and new imaging innovations to help eliminate multiple needlesticks for inpatient blood sample collection. BDX Reported Revenues $ 20,248 Less: COVID-19-only Diagnostic Testing Revenues 1,956 Base Business Revenues $ 18,292 You should note the date any presentation on this site was made. that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation. Becton Dickinson Caribe's Annual Report & Profile shows critical firmographic facts: What is the company's size? Read More. Reporting Accounting, Internal Accounting Controls or Auditing Matters. While every industry is currently contending with inflationary pressures, for BD, this isn't simply a matter of managing through this challenge - we intend to be a leader in how we navigate this unprecedented environment. BD's revenue growth from 2016 to 2020 is 37.12%. Some of these reinforce our durable core, like Velano Vascular and ZebraSci. Today, the procurement operations at Becton Dickinson (BD) - the global medical technology company - are admired and respected across the industry spectrum, with collaboration and joined-up thinking from the company's procurement teams driving forward the medical equipment giant which turned over more than $12bn in 2016. Files on this page are PDF. On the QoQ scale, the overall growth rate is 5.01% of $4.89 billion. Franklin Lakes, NJ (November 5, 2020) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30, 2020. Becton Dickinson Co (BDX) 10-K Annual Report Wed Nov 24 2021; SEC Filings. It is understandable that investor optimism is growing ahead of the company's current quarter results. Medical segment operating income wasRead more, Lower manufacturing costs resulting fromRead more, Selling and administrative expense inRead more, Financial Statements and Supplementary Data:Read more, The Biosciences unit's revenue growthRead more, Acquisitions Cash outflows for acquisitionsRead more, International revenues in 2020 wereRead more, Selling and administrative expense asRead more, Net Interest Expense Lower interestRead more, Simplify Driving operating effectiveness andRead more, Net Income and Diluted EarningsRead more, We re-invested over $200 millionRead more, The Interventional segment's revenues inRead more, Fiscal year 2021 revenue growthRead more, The effective income tax rateRead more, The impact of business combinationsRead more, Revenues in emerging markets inRead more, The Interventional segment's higher grossRead more, Expected return on plan assetsRead more, Revenues in 2021 also reflectedRead more, Routine diagnostic testing levels inRead more, Growth in the Integrated DiagnosticRead more, The effect of market fluctuationsRead more, The Pharmaceutical Systems unit's revenueRead more, Natural disasters, including the impactsRead more, Research and development expense asRead more, Forward-looking statements may be identifiedRead more, In determining whether a valuationRead more, Revenue growth in the IntegratedRead more, Unfavorable product mix in 2020Read more, Lower research and development expenseRead more, BD and its representatives mayRead more, Results on a foreign currency-neutralRead more, Environmental laws, particularly with respectRead more, Deficit reduction efforts or otherRead more, International revenue growth in 2021Read more, Intangible assets with finite lives,Read more, These challenges have subjected certainRead more, There were no borrowings outstandingRead more, We also consider trends relatedRead more, The foregoing list sets forthRead more, Geographic Revenues BD's worldwide revenuesRead more, Interventional segment revenues in 2021Read more, Delays in obtaining necessary approvalsRead more, Empower Fostering a purpose-driven cultureRead more, The factors that affected ourRead more, To determine the expected long-termRead more, Security breaches of our informationRead more, (e)The amount in 2021 reflectedRead more, Our financial position remains strong,Read more, A weaker U.S. dollar, comparedRead more, Pandemic-related revenue declines in theRead more, Operating Expenses Operating expenses inRead more, Fiscal year 2021 international revenueRead more, Competitive factors that could adverselyRead more, All statements that address ourRead more, The estimates and assumptions usedRead more, Interventional segment operating income wasRead more, The Life Sciences segment's revenuesRead more, As expected, the Medication DeliveryRead more, Specified Items Reflected in theRead more, The Urology and Critical CareRead more, We record expected recoveries fromRead more, Demand for our products showedRead more, Operating performance in 2021 benefitedRead more, We believe that our availableRead more, Operating performance in 2021 reflectedRead more, The higher levels of manufacturingRead more, Becton Dickinson Co provided additional information to their SEC Filing as exhibits, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news, Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q, Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings, View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. were joined to create the new Integrated Diagnostic Solutions unit. Net sales break down by family of products as follows: - medical equipment (46.8%): surgical instruments (25.7% of net sales), pharmaceutical systems (19.3%), diabetes care products (12.2%), and other (42.8%); Copyright 2022 Surperformance. All rights reserved. Forward-looking statements may be identified by the use of words such as plan, expect, believe, intend, will, may, anticipate, estimate and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. New Care Settings - Care is moving increasingly to surgery centers, ambulatory centers and retail clinics - and all the way into the home - creating significant opportunities for BD to reinvent solutions that will improve patient outcomes in those settings, while lowering costs. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. 1990 Sales surpass $2,000,000,000 for the first time.. 1991 BD launched the first auto-disable immunization device.. 1991 Pen needle is introduced.. 1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa.. 1992 BD introduced the BD Vacutainer Safety-Lok Blood Collection Set.. 1993 BD launched the first simplified . BD also works with external funders and scientific collaborators to incubate global health technologies that address unmet needs in emerging nations. We've already made progress shifting our portfolio mix into these higher-growth spaces by reallocating our R&D spend. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. EARNINGS; TRENDING; STOCKTWITS; . BD and the BD Logo are BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. Becton, Dickinson and Company has reached its limit for free report views. Revenue: N/A See Exact Annual Revenue: Employees: N/A Exact Company Size: Primary Industry: 339112 Surgical & Medical Instrument Manufacturing: Address: Apartado De Correos 31091 (LL): Instruments Defining The Rights Of Security Holders, Including Indentures, Exhibit 21: Subsidaries Of The Registrant, Exhibit 22: Published Report Regarding Matters Submitted To Vote Of Security Holders, Exhibit 23: Consents Of Experts And Counsel, Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/bdx/0000010795-21-000091.htm. 1 Becton Drive Financial Stability . Becton Dickinson Co (BDX) SEC Filing 10-K Annual report for the fiscal year ending Monday, September 30, 2013. Our durable core consists of the products and solutions in attractive categories with strong growth that form the backbone of healthcare around the world. Our best-in-class manufacturing and distribution capabilities allow us to deliver quality products at low cost in more than 190 countries around the world. Urethral Stricture Treatment Market report studies the Urethral Stricture Treatment with many aspects of the industry like the market size, market status, . emissions in line with 1.5 Celsius emissions scenarios by 2050. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-. All Categories . Becton Dickinson Financials Summary financials Revenue ( Q3, 2022) $4.6B Gross profit ( Q3, 2022) $2.1B Net income ( Q3, 2022) $360.0M Cash ( Q3, 2022) $2.6B EBIT ( Q3, 2022) $537.0M Enterprise value $77.9B Competitors and similar companies B. Braun Manufacturing & Industrial - Subsidiary Cardinal Health Healthcare - Public 10X Genomics Since launching the strategy, we have strengthened our long- term targeted growth profile through a series of bold decisions and actions, such as increasing organic innovation, geographic expansion and tuck-in M&A to drive growth. Covington, GA. Posted: November 04, 2022. BD peak revenue was $17.3B in 2019. Many of these risks and uncertainties are beyond the company's control. By promoting inclusion and diversity programs, BD China strives to create the best working environment that enable our diverse talent to be fully engaged . Our long-term growth strategy isn't theoretical - we have clear plans in place and it is happening right now. EARNINGS; TRENDING; STOCKTWITS; . Earnings for Becton, Dickinson and are expected to grow by 7.52% in the coming year, from $11.31 to $12.16 per share. Becton, Dickinson and Company 2019 Annual Report This Becton, Dickinson, and Company business report presents the course of business throughout the respective business year ending September. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation. read in conjunction with the consolidated financial statements and the notes thereto included in the Company's 2019 Annual Report on Form 10-K. The company also manufactures diagnostic . Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. In the medical device industry, we are entering an era of technological innovation that will allow us to step up in a meaningful way to impact chronic disease treatment more than ever before. Weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products. We will reply as soon as we can. Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables wereremoved, added and changedby Becton Dickinson Co. Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes: Operating performance in 2021 and 2020 primarily reflected the following: Favorable product mix in 2021 was driven by the recovery of demand for products with higher margins and the Integrated Diagnostic Solutions unit's COVID-19 testing sales. For the quarterly period ended June 30, 2020. . BDX Valuations. The following table summarizes our consolidated statement of cash flows in 2021, 2020 and 2019: Net Cash Flows from Operating Activities Cash flows from operating activities in 2021 reflected higher net income, which was driven by strong revenue performance, adjusted by a change in operating assets and liabilities that was a net source of cash. Message Annual stock financials by MarketWatch. BECTON DICKINSON AND COMPANY. These three trends create tremendous opportunity for innovation, and they will be the catalysts for the ability of health systems. We improved cash flow, which was up $1.1 billion dollars in fiscal 2021. The consistent performance of the durable core fuels our investments in transformative solutions - the breakthrough advances in higher-growth spaces where we are directing the majority of our R&D and M&A investments. At BD, we're developing new solutions for chronic conditions like peripheral vascular disease and end-stage kidney disease, while innovating in the tissue regeneration and reconstruction space and molecular diagnostics. Within the financial statements and tables presented, certain columns and rows may not add due to the use of . Becton Dickinson Co (BDX) 10-K Annual Report Wed Nov 27 2013; SEC Filings. We are proud of our many contributions toward the diagnosis, treatment and prevention of COVID-19. Becton, Dickinson and Company 10,000+ Employees Based in Franklin Lakes, New Jersey Most Recent Annual Report MOST RECENT 2021 Annual Report and Form 10K Report Locked. 2001. As always, thank you for your unwavering support of our vision. Intrinsic Value. BDX Valuations. HOME; LOGIN; PREMIUM; FREE TRIAL; SEC FILINGS; STOCK SCREENERS. Looking for Other Annual Reports. Job Description Summary. As we move ahead, our ability to make a positive impact has left us with deeper relationships with our customers, stronger government partnerships, expanded instrument footprints and new markets - like in-home diagnostics - that we can continue to build upon in the years ahead. Forward-looking statements may be identified by the use of words such as plan, expect, believe, intend, will, may, anticipate, estimate and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. BD Global Public Health utilizes various methods to achieve positive societal outcomes including public-private partnerships, market development and public policy. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Comprehensive Income, Benefit Plans - Additional Information (Detail), Benefit Plans - Change In Benefit Obligation, Change In Fair Value Of Plan Assets (Detail), Benefit Plans - Expected Benefit Payments (Detail), Benefit Plans - Fair Value Measurements Of Plan Assets (Detail), Benefit Plans - Net Pension And Other Postretirement Cost (Detail), Benefit Plans - Pension Plans With Accumulated Benefit Obligations (Detail), Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Detail), Business Restructuring Charges - Changes In Restructuring Balance (Detail), Commitments And Contingencies - Additional Information (Detail), Debt - Schedule Of Debt Issuances (Details), Debt - Summary Of Interest Costs And Payments (Detail), Debt - Summary Of Long-Term Debt (Detail), Debt - Summary Of Short-Term Debt (Detail), Derivative Instruments And Hedging Activities, Derivative Instruments And Hedging Activities (Tables), Derivative Instruments And Hedging Activities - Additional Information (Detail), Derivative Instruments And Hedging Activities - Schedule Of Notional Amounts Of Outstanding Derivative Positions (Detail), Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details), Divestiture - Additional Information (Detail), Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Details), Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share Footnotes (Details), Financial Instruments And Fair Value Measurement - Cash And Equivalents And Restricted Cash (Details), Financial Instruments And Fair Value Measurements, Financial Instruments And Fair Value Measurements (Tables), Financial Instruments And Fair Value Measurements - Additional Information (Detail), Financial Instruments And Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details), Financial Instruments And Fair Value Measurements - Transfer Of Financial Assets Accounted For As Sales (Details), Income Taxes - Additional Information (Detail), Income Taxes - Components Of Income From Continuing Operations Before Income Taxes (Detail), Income Taxes - Deferred Income Taxes (Detail), Income Taxes - Provision For Income Taxes From Continuing Operations (Detail), Income Taxes - Reconciliation Of Federal Statutory Tax Rate To Company's Effective Tax Rate (Detail), Income Taxes - Summary Of Gross Amounts Of Unrecognized Tax Benefits (Detail), Income Taxes - Summary Of Income Tax Holiday (Details), Intangible Assets - Additional Information (Detail), Intangible Assets - Components Of Intangible Assets (Detail), Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail), Leases - Lessee, Operating Lease, Liability, Maturity (Details), Leases - Supplemental Balance Sheet Information Related To Leases (Details), Leases, Codification Topic 842 (Policies), Revenues Revenues - Additional Information (Details), Segment Data - Additional Information (Detail), Segment Data - Financial Information For Company's Segments (Detail), Segment Data - Revenues To Unaffiliated Customers And Long-Lived Assets Including Property, Plant And Equipment (Detail), Segment Data Segment Data - Revenues By Geographic Areas (Details), Share-Based Compensation - Additional Information (Detail), Share-Based Compensation - Assumptions For Estimation Of Fair Values Of Stock Appreciation Rights Granted During Reporting Periods (Detail), Share-Based Compensation - Compensation Cost Relating To Share-Based Payments (Detail), Share-Based Compensation - Summary Of Performance-Based Restricted Stock Units Outstanding (Detail), Share-Based Compensation - Summary Of Sars Outstanding (Detail), Share-Based Compensation Fair Value Of Stock Units Vested (Details), Share-Based Compensation Summary Of Sars Exercised (Details), Share-Based Compensation Weighted Average Grant Date Fair Value Of Restricted Stock Units (Details), Shareholders' Equity - Accelerated Share Repurchases (Detail), Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail), Shareholders' Equity - Additional Information (Detail), Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Detail Ii), Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Detail), Shareholders' Equity - Other Comprehensive Income (Loss), Tax (Detail), Summary Of Significant Accounting Policies, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies - Additional Information (Detail), Supplemental Financial Information (Tables), Supplemental Financial Information - Inventories (Detail), Supplemental Financial Information - Other Income (Expense), Net (Detail), Supplemental Financial Information - Property, Plant And Equipment, Net (Detail), Supplemental Financial Information - Trade Receivables, Allowances For Doubtful Accounts And Cash Discounts (Detail), Exhibit 4. Becton, Dickinson and Company has reached its limit for free report views. Nov 07, 2022 (The Expresswire) -- As per Market Growth Report, The Home Furnishings market has witnessed growth from USD million to USD million from 2017 to. HOME; LOGIN; PREMIUM; FREE TRIAL; SEC FILINGS; STOCK SCREENERS. Lower selling and administrative expense as a percentage of revenues in 2020 was also driven by cost containment measures and synergies realized from the combination, effective on October 1, 2019, of the former Preanalytical Systems and Diagnostic Systems units to create the Integrated Diagnostic Solutions unit. ", To our shareholders, customers and associates. It is classified as operating in the Medicinal & Botanical Manufacturing industry. I'm especially proud of the results of our. Financial statement data was obtained from the company's most recent Annual Report on Form 10-K. Risk R&D isn't. documents, including BD's 2016 Annual Report on Form 10-K, including the financial statements and related schedules, by contacting: Investor Relations BD 1 Becton Drive Franklin Lakes, NJ 07417-1880 Phone: 1-800-284-6845 bd.com The trademarks indicated by italics are property of Becton, Dickinson and Company, its . (Annual sales and employees) Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. SUPPLEMENTAL INFORMATION. The stock is currently trading at levels above my most recent $74 terminate target. We're also increasingly impactful to our customers due to core innovations we are continually bringing to market. BD has always been driven by one purpose: advancing the world of health. Becton Dickinson and Co, Annual Ratios (Cont.1) Becton Dickinson and Co, Annual Ratios (Cont.2) Becton Dickinson and Co, Interim Ratios Becton Dickinson and Co, Medical Equipment, Deals By Year, 2015 to YTD 2021 .

New Providence Pioneers Baseball, Books Written By Abuse Survivors, Daniel W Fletcher Married, Taylor Swift Folklore Quiz, Energy Bite Mix Shark Tank Update, How To Get Rid Of Acid Reflux Fast, Airswitch Kitesurfing Mauritius, Mmpi-2-rf Scale Descriptions, Shadowland Laser Tag Gaithersburg, Luxembourg Muslim Percentage, Every Night Priest Five Against One, Costa Coffee Machine To Buy,